Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib

Abstract

BACKGROUND Sorafenib can be considered as the effective option of treatment in patients with metastatic radioiodine refractory differentiated thyroid cancers. The cutaneous manifestations of Sorafenib include rash, desquamation, hand foot skin reactions, pruritus, alopecia and erythema. We report the first case of hypopigmentation related to sorafenib… (More)
DOI: 10.1186/1472-6823-13-29

Topics

2 Figures and Tables